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Abstract 
 
The present work aims at evaluating the possible role of the endocannabinoid system 
(ECS) and its effects on the control of angiogenesis in lung carcinoma.  
Worldwide, lung cancer is the most common cause of cancer-related deaths. The target of 
angiogenesis in solid tumours, including lung cancer, represents a new promising strategy 
(Giaccone, 2007), since tumour angiogenesis is a process necessary for the growth of the 
solid tumours. The implant of the tumoural cells in a tissue leads to a release of pro-
angiogenic factors that activate endothelial cells, allowing the formation of new capillaries 
and their subsequent stabilization. Therefore, angiogenesis supplies oxygen and nutrients 
to the tumour mass. The therapeutic efficacy of anti-angiogenic drugs has been 
demonstrated in clinical studies and anti-angiogenic compounds currently represent an 
important coadjuvant approach to the standard anti-cancer therapies. A promising class of 
anti-angiogenic compounds is represented by Cannabinoids (CBs), all the natural 
compounds, synthetic and endogenous factors exhibiting the same biological activity of 
the derivatives of Cannabis Sativa L., Marijuana (De Filippis and Iuvone 2009). ECS is 
formed by receptors, CB1 and CB2, their ligands mainly anandamide (AEA) and 2-
arachidonylglycerol (2-AG) and the main enzymes  involved in the metabolism and 
transport of these endogenous ligands.  
On the basis of these evidences this Ph.D. study focused attention on the deregulation of 
ECS associated with the tumoral angiogenesis in a murine model of lung carcinoma to 
strengthen the numerous evidences  indicating  CBs as possible new coadjuvant molecules 
to the classic anti-cancer therapy. 
In this study, a model of lung cancer induced in C57BL/6 mice injected with Lewis Lung 
Carcinoma cells was used. The deregulation of the ECS  was evaluated during the various 
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stages of tumor growth and correlate to the process of angiogenesis. The experiments 
show, for the first time, a strong deregulation of ECS in lung cancer; in fact, there is a 
significant increase in the levels of the MAGL enzyme, involved in the degradation of the 
main endogenous ligand for these receptors, 2-AG, and the expression of the CB2 
receptor. This deregulation  is, closely, associated with the angiogenic process, given that 
it is highlighted in the second phase of tumor progression, a phase in which the tumor 
mass requires oxygen and nutrients for its growth, and the CB2 receptor seems to be the 
protagonist of this regulation. Considering these results, we tried a therapeutic approach 
with a selective agonist of the CB2 receptor, JWH133. The treatment with JWH133 
improved tumor parameters reducing the principal angiogenic markers, such as VEGF, 
MMP-9, MMP-3, CXCL16, Endoglin, angiopoietin, aFGF, bFGF, SDF-1. The CB2-
mediated activity of JWH133 was confirmed through the use of CB2 knockout animals in 
which the tumor was induced in the same experimental conditions. An alternative strategy 
was also used in the agonist treatment, to have a pharmacological intervention only in the 
tumor mass, the area where the ECS appears deregulated. This alternative approach 
provided for the use of an inhibitor of MAGL, JZL184. The data demonstrates that 
JZL184 reduces the tumor mass and the angiogenic process, similarly to the JWH133.  
 
In conclusion, the data here obtained strengthen the possibility to use cannabinomimetics 
molecules as adjuvants in standard anti-tumor therapies n order to control the ECS 
deregulation, to reduce angiogenesis associated with tumoral conditions and, 
consequently, to improve the pathological condition. Moreover, these compounds have 
lower price and less side effects compared to currently use anti-angiogenic agents. 
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Abbreviations 
 
AA      Arachidonic acid 
AEA     Anandamide 
aFGF      Acidic Fibroblast Growth Factor 
AMT     Anandamide membrane transporter 
Angs      Angiopoietins 
bFGF (FGF-2)     basic Fibroblast Growth Factor 
ATP     Adenosine triphosphate 
BBB     Blood-brain barrier 
BM      Basement Membrane 
BrdU      BromodeoxyUridine 
CBs      Cannabinoids 
CBD     Cannabidiol 
CNS      Central Nervous System 
COX-2     CycloOXygenase-2 
CD105     Endoglin 
CXC              Chemokines 
DAGL-     Diacil glycerol lipase 
DMEM      Dulbecco's Modified Eagle Medium 
ECM      ExtraCellular Matrix 
EC      Endothelial Cell 
eCBs      Endocannabinoids 
ECS      Endocannabinoid System 
EGF     Epidermal Growth Factor 
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EGFR      Epidermal Growth Factor Receptor 
ELISA      Enzyme-Linked ImmunoSorbent Assay 
EPCs      Endothelial Progenitor Cells 
ET      Endothelin 
FAAH     Fatty acid hydrolase amide 
FAK     focal adhesion kinase  
FBS      Foetal Bovine Serum 
FDA     Food and Drug Administration  
GCSF     Granulocyte-colony stimulating factor 
GM-CSF Granulocyte-macrophage colony-stimulating 
factor  
HIF1-     Inducible Hypoxic factor 
HDL     High Density Lipoprotein 
HSPG      Heparin Sulphate ProteoGlycans 
IAR     Intussusceptive arborization intussusceptive  
IBR     Intussusceptive branching  
IMG     Remodeling microvascular growth 
IFN      Interferon 
ILs      Interleukins 
JNK     c-Jun N-terminal kinase 
LDL     Low Density Lipoprotein 
MAGL     Mono-acil glycerol lipase 
MAPK     Mitogen-activated protein kinases  
MMPs      MatrixMetalloProteases 
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MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-
Dipheniltetrazoliumbromide 
mTOR Mechanistic target of rapamycin 
NAPE-Phospholipase D N-acyl phosphatidylethanolamine phospholipase 
D 
NO      Nitric Oxide 
NOs      Nitric Oxide syntase 
OPN     Osteopontin 
PAI-1     Plasminogen activator inhibitor-1 
PECAM-1     Platelet endothelial cell adhesion molecule 
PlGF     Placental growth factors 
PBS      Phosphate Buffer Solution 
PDGF      Platelet-Derived Growth Factor 
PI3K      Phosphatidyl-Inositol 3 Kinase 
TAF     Tumor Angiogenesis Factor  
THC     Tetrahydrocannabinol 
TIMPs     Tissue inhibitor of metalloproteinases 
TKI     Tyrosine kinase inhibitor 
TRPV1     Transient receptor potential vanilloid-1 
TSP-1/-2     Trombospondin-1/-2 
TGF-α      Transforming Growth Factor-α 
TGF-β     Transforming Growth Factor-β 
TNF-α      Tumor Necrosis Factor-α 
      TKI            Tyrosine kynase inhibitors  
uPA     urokinase-type PA 
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VEGF      Vascular Endothelial Growth Factor 
VEGFR      Vascular Endothelial Growth Factor Receptor 
VPF     Vascular permeability factor 
VR1     Type 1 vanilloid receptor 
2-AG     2-Arachidonyl glycerol 
2-AGE     2-Arachidonyl glyceryl ether 
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1. Introduction 
 
1.1 Angiogenesis 
1.1.1 Angiogenesis: an overview 
Angiogenesis refers to the building of new capillary branches from existing blood vessels; in 
physiological conditions, angiogenesis occurs primarily in embryo development, during 
wound healing and in response to ovulation. However, pathological angiogenesis, or the 
abnormal rapid proliferation of blood vessels, is implicated in over 20 diseases, including 
cancer, psoriasis and age-related macular degeneration (Bouïs et al., 2006). 
The angiogenic process is made up of different steps: 
 Start of angiogenic reaction; 
 proliferation and migration of endothelial cells; 
 lumen acquisition, stabilization, maintenance, differentiation and remodeling of 
nascent vessel. (Ucuzian et al.,2007; Carmeliet et al.,2009; Pugh and Ratcliffe, 2003). 
Start of angiogenic process 
The beginning of angiogenic cascade is due to hypoxic events, inflammation causes or stress; 
all these stimuli promote the destabilization of pre-existing vessels and loss of junctions 
between endothelial cells. Endothelial cells are activated to produce cytokines and growth 
factors that cause modification of pre-existing vessels (Milkiewicz et al., 2006),  increase of 
vascular permeability, a process involving nitric oxide (NO) and allow of the extra-vasation 
of plasma proteins that lay down a provisional scaffold for migrating endothelial cells. At this 
point, plasminogen activator, matrix metallo-proteases (MMPs), chymase or heparanase 
families influence angiogenesis by degrading basal membrane and extracellular matrix 
molecules as well as by activating or liberating growth factors sequestered within the 
extracellular matrix (Coussens et al. 1999). Each stage is regulated in physiological  
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condition, while this regulation is lost in pathological condition, such as, tumor growth and 
metastasis (Liekens et al., 2001) 
Proliferation and migration of endothelial cells  
Cell adhesion to many matrix components and intra-cellular remodulation of cytoskeletal 
filaments, bring cells to migrate. In this phase some receptors placed on the cell surface 
membrane, such as integrines, in particular the classes of 3 5, over-expressed on 
proliferant endothelial cells play an important role (Nisato et al., 2003). The migration can be 
promoted by a series of mechanical perturbations on matrix-cell contact. During angiogenesis 
proteins proteolysis of basal membrane takes a local thinning of the structure that results at 
certain points in a distortion of cell membrane such as the alteration of tractional forces 
(Ingber et al., 2002). The mechanical signal so originated, is converted intracellularly in 
biochemical stimuli that trigger the movement (Shin et al., 2001). Endothelial cells "guide" 
then proceed in interstitial space, followed by proliferating cells. The collapse of the extra-
cellular matrix (ECM) produces an increase in the extracellular concentration of various 
soluble pro-angiogenic mediators, which feed and strengthen the signaling pathways 
underlying the chemotactic and proliferative process.  
Lumen acquisition, stabilization, maintenance, differentiation and remodeling of 
nascent vessel 
The proliferation of endothelial cells, already, occurs in the early stages of the angiogenic 
process and continues throughout the period of elongation of the neo- capillary. Immediately, 
along sketch vascular cells are organized in order to create the lumen of the vessel. The 
appearance of this structure may occur through a process of fusion of cytoplasmic vacuoles 
(channeling intracellular) or by appending more cells around a central tubule (channeling 
intercellular) (Egginton & Gerritsen, 2003).  
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The tissue perfusion is restored at the expense of  anastomosis between the vascular 
endothelium that advances, and pre-existing vessels; thus, the merger of two capillaries 
branches occur to create a new channel through blood can flow.  
The final phase of maturation and stabilization of the capillary tube involves the deposition of 
a new basement membrane and the re-establishment of the contact between the adherent cells. 
In order to delineate the vessel lumen, distribution and type, adhesion factors determine the 
polarity of the endothelial cells, by discriminating the side luminal from the not- luminal 
(Liekens, 2001). 
The stabilization of new capillary is the last phase of angiogenic process; several factors, as 
Angiopoietin 1 (Ang1), Angiopoietin 2 (Ang2) and placental growth factor (PlGF), play a 
pivotal role in this events (Milkiewicz, 2006). When the nascent vessel is formed, the 
proliferation and migration of endothelial cells are inhibited and a new basal membrane is 
secreted (Bouïs, 2006). To obtain a functional vascular network, the new vessels are 
remodeling to become mature; this maturation is due to Platelet-Derived-Growth Factor 
(PDGF), that also stimulates the recruitment of perycites and smooth muscle cells that 
stabilize vessels (D‟Andrea 2006).                                                                                                                                                                                                                                                                                                                                                                        
             
                        Fig.1: Angiogenic cascade scheme 
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1.1.2 Formation of new blood vessels 
Angiogenic process occurs not only as previously described, but also by another two different 
mechanisms: 
 intussusception, 
 starting from endothelial precursors which come from bone marrow. 
Intussusception 
Intussusception is a process in four phases; it starts with the invagination of the capillary wall 
in two opposite points. In this way, an inter-endothelial contact-zone, into the lumen vessel is 
formed, which will be perforated centrally. The area between the new two blood vessels is 
rich in perycite and fibroblaste responsible for the deposition of collagen fibers as the main 
component of the extracellular matrix (Djonov et al., 2002).  
 
 
Fig.2: Synthetic representation of new blood vessels formation by intussusceptions mechanism 
 
 
Different aspects of angiogenesis and remodeling in perfused microvascular systems are 
accomplished via three modes of intussusceptions: intussusceptive microvascular growth 
(IMG), intussusceptive arborization (IAR), and intussusceptive branching remodeling (IBR). 
IMG can rapidly expand a capillary plexus and produce a large endothelial surface without 
altering capillary dimensions. IAR can generate feed vessels from the capillary plexus by 
changing their dimensions, position, and identity and thus, influence “endpoint density” of the 
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supplying network. Finally, IBR can modulate the position of and diameters at branching 
points in larger microvessels and can, therefore, influence pre- and postcapillary transport 
properties. Moreover, IBR can lead to the removal of branches, and this process of vascular 
pruning is of considerable importance to achieving transport efficiency (Kurz et al., 2003). 
Endothelial precursors  
The process about the formation of new blood vessels is, also, due to the recruitment of 
endothelial precursors: endothelial progenitors cells (EPCs). These cells come from 
emathopoiteic staminal cells and they are able to migrate from bone marrow to the damaged  
area. Neovascularization is due to both the capacity of these precursors to differentiated 
themself in endothelial cells, incorporated then in newly formed vessels, and  the secretion of 
growth factors. EPCs are, in fact, able to release growth factors, as vascular endothelial 
growth factors (VEGF), contributing to the growth of the vessel. VEGF promotes 
vasculogenesis by promoting EPC chemotaxis, recruitment (Li et al., 2006), and vessel 
formation. The cells received at the point of sprouting take advantage of the increase in local 
permeability, to escape into the interstitial space and clustering; some of them will be 
integrated in the neo-formed endothelial monolayer while a part of the EPC can be traced in 
the perivascular structure layers (Murasawa & Asahara, 2005; Schatteman et al., 2004).  
            
                     
                               Fig. 3: Angiogenesis by mobilization of EPCs from the bone marrow 
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1.2 Angiogenic switch 
The angiogenic process is a fine regulated process, strictly controlled by a balance between 
stimulatory and inhibitory factors; a change of this harmony can caused an “angiogenic 
switch” (Bergers and Benjamin, 2003; Ribatti et al., 2007) allowing the formation or the non-
formation of new blood vessels (Mandriota and Pepper, 1997), causing damage (Hanahan and 
Folkman, 1996). Many of the intra-cellular stimuli associated with the “angiogenic switch” 
shift the balance to the activation of angiogenesis; it is possible to identify these factors as 
pro-angiogenic or, those inhibiting them (anti-angiogenic mediators). 
                     
 
                         
                                     Fig. 4: A ngiogenic switch  
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Pro-angiogenic factors can be divided in two groups: direct and indirect factors; the first 
directly stimulate the proliferation and migration of endothelial cells; the second, promote the 
activation of endothelial cells by other factors (Folkman and Shing, 1992).  
The main pro-angiogenic factors (table 1) are:    
  
VEGF (Vascular Endothelial 
Growth Factor) 
increase the permeability and migration of 
endothelial cells, stimulate and promote 
angiogenesis 
   
Ang1 (Angiopoietin1) stimulate the formation of endothelial cells and 
increase the stability of endothelium 
  
Ang2 (Angiopoietin2) destabilizes endothelium in presence of VEGF 
  
aFGF, bFGF stimulate angiogenesis in vivo, the proliferation 
and formation of tubes and the production of 
collagenase in endothelial cells; also, increase the 
migration of endothelial cells 
  
PDGF increases the formation of perycite and smooth 
muscle cells and augments the stability of 
capillary walls; also, induces the expression  of 
VEGF and VEGFR-2 
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TGF-β supports the fibroblaste growth and inhibits the 
proliferation and migration of endothelial cells; 
supports the stability of the capillary wall 
  
TNF- Stimulates angiogenesis in vivo and the formation 
of endothelial cells in vitro 
  
EGF, TGF- Stimulate the proliferation and migration of 
endothelial cells 
  
G-CSF, GMCSF Stimulate the proliferation and migration of 
endothelial cells 
  
Angiogenin Supports the link and extension between 
endothelial cells  
  
Tissue factor Contributes to the formation of the vasculature of 
the yolk sac 
Table 1: The main pro-angiogenic factors 
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On the other hand, there main  anti-angiogenic factors may be classified as follows (Table 2): 
  
ANG2  Antagonist of Ang1 
  
TSP-1 e -2 Inhibits migration, growth, survivor and adhesion 
of endothelial cells   
  
Angiostatin Inhibits tumoral angiogenesis and proliferation 
  
Endostatin Inhibits the activation of endothelial cells; 
promotes apoptosis; inhibits the activity of 
metallo-proteases 
  
Anti-trombin Inhibits angiogenesis and tumoral growth 
  
IFN-α,-β,-γ; IP-10; IL-4, IL-12, IL-18 Inhibits the migration of endothelial cells and 
down-regulate bFGF 
  
TIMPs Inhibit metallo-proteases 
  
Tumastatin Inhibits angiogenesis and promotes apoptosis 
Table2: The main anti-angiogenic factors 
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1.2.1 Vascular Endothelium Growth Factor 
VEGF, also known as Vascular Permeability Factor (VPF), is the most important mediator in 
angiogenic process since it is able to regulate all events in angiogenesis. VEGF is a survival 
factor for ECs, both in vitro and  in vivo (Plate et al., 1992; Shweiki et al., 1992). In vitro, it 
prevents apoptosis and its activity is mediated by the phosphatidylinositol (PI)-3Akt pathway 
(Gerber et al., 2002). In vivo, VEGF induces angiogenesis as well as permeabilization of 
blood vessels, and plays a central role in the regulation of vasculogenesis. This factor has, 
also, an effect on bone-marrow-derived cells; it promotes monocyte chemotaxis (Ferrara et 
al., 2003), inhibits antigen presenting cells, inducing a decrease of immunity response 
(Ferrara et al., 1997).  
Hypoxic signal is the first event that induces an increase of VEGF expression and this causes 
an increase of its mRNA. The transcriptional regulation of VEGF is mediated by hypoxia 
inducible factor-1 (HIF-1); so when HIF-1 is activated a cascade of events starts; in 
particular, HIF-1 is involved in an iper-activation of VEGF in pathological conditions, such 
as cancer. In fact, the proliferation, the migration and the permeability of endothelial cells, 
inducted by VEGF, carry out a critical role in angiogenic process (Keyt et al., 1996; 
Bernatchez et al., 1999; Waltenberger et al., 1994).  HIF-1, remarkably, produces VEGF and 
contributes to the formation of vascular tubes in embryogenesis as well as in adults.  
VEGF is not a single protein, but a small group of several peptide growth factors of different 
amino-acids in length and type. It was firstly discovered in 1983 as vascular permeability 
factor (Senger et al., 1983) and in 1989 it was characterized as an endothelial cell mitogen and 
called vascular endothelial growth factor (Gerber et al., 2002). The VEGF family‟s is made up 
of six members: VEGF-A (o VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E e PlGF.  
All of these type of VEGF due their function to the bind with three tyrosine-kinase receptors: 
VEGFR-1 (FLT-1), VEGFR-2 (KDR/FLK-1) and VEGFR-3 (or Flt-4), which are expressed 
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almost exclusively in endothelial cells. The bind to the ligand allows a conformational 
change, causing dimerization that triggers a process of autophosphorylation. The receptor, 
thus, activatd can promote the release of a several second messenger that causes a biological 
response.  
VEGF-A act, principally, on the angiogenic control; alternately spliced isoforms of 121, 145, 
165, 189 and 206 aa have been identified in humans (Shima et al., 1996; Robinson et al., 
2001). VEGF165 is the most abundant isoform, followed by VEGF121; VEGF206 is expressed 
during embryonic progress (Houck et al., 1991), while  isoform 145 has been observed in cell 
lines derived from cancers of the female reproductive organs (Poltorak et al., 1997) and its 
expression seems to be more restricted. VEGF189 displays a higher affinity to heparin and 
heparin-sulfates than VEGF145 or VEGF 165; it is sequestered on heparin-sulfate proteoglycans 
of cell surface in the extracellular matrix protecting VEGF to enzymatic degradation 
(Robinson et al., 2001). VEGF-A binds with high affinity VEGFR-1 and -2 and plays an 
essential role in vasculogenesis and angiogenesis. It has also been shown to induce 
lymphangiogenesis through VEGFR-2. VEGF-B is, principally, involved in monocyte 
chemotaxic process (Ferrrara et al., 2001); it is expressed in several tissues and most 
abundantly in the heart, brain, skeletal muscle, and kidney, and it occurs as two splice 
isoforms of 167 and 186 amino acids, respectively (Olofsson et al., 1996). Because VEGF-B 
binds VEGFR-1, it may have a role in the regulation of blood vessel physiology. The ability 
of VEGF-B to heterodimerize with VEGF is consistent with the conservation of the eight 
cysteine residues involved in inter- and intramolecular disulfide bonding. Furthermore, the 
coexpression of VEGF-B and VEGF in many tissues suggests that VEGF-B/VEGF 
heterodimers occur naturally. The formation and cell association of such heterodimers may 
affect the formation of VEGF homodimers and thus indirectly control release and 
bioavailability of VEGF. VEGF-B binds, selectively, VEGFR-1 and induces an increase of 
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urokinase-type PA (uPA) and plasminogen activator inhibitor-1(PAI-1) expression, 
suggesting an its role in the degradation of the matrix process and in the migration of 
endothelial cells (Olofsson et al., 1998); it, also, overlaps VEGF-A activities by activating 
VEGFR-1 (Olofsson et al.,1999). VEGF-C and VEGF-D are involved in lymphangiogenesis, 
its binds to and induces tyrosine phosphorylation of VEGFR-3 (Makinen et al., 2001). A 
correlation between VEGF-C and VEGF-D expression, tumor lymphangiogenesis and the 
formation of metastases in regional lymph nodes has been described in a range of human 
tumors, including malignant melanoma and lung, breast, colrectal and gastric carcinomas 
(Stacker et al., 2002). VEGF-C and VEGF-D are both angiogenic via VEGFR-2 and VEGFR-
3, and lymphangiogenic (primarily VEGF-D) via VEGFR- 3 (Hamada et al., 2000; Achen et 
al., 2002). VEGF-E is codificated by parapox-Orf-virus gene and act, only, on VEGFR-2. 
PlGF induces angiogenesis in vivo and it is, principally, express in placenta and tumors.  
 
                                                  PIGF    VEGFB    VEGFA   VEGFE  VEGFC  VEGFD 
 
 
 
 
 
 
 
      
            VEGFR1/VEGFR1   VEGFR2/VEGFR2   VEGFR3/VEGFR3  
                                                         (FLT1/FLT1)               (KDR/KDR)           (FLT4/FLT4) 
 
                                                            Fig 5: VEGF receptors and its ligands 
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1.2.2 Other pro-angiogenic  factors 
There are several other growth factors thought to be involved in angiogenesis. Many factors 
act directly on endothelial cells as cytochine, chemokine and angiogenic enzymes.  
Fibroblast Growth Factor 
Currently, the family of fibroblast growth factors (FGF), has at least 22 members, all capable 
of acting as a pleiotropic molecules on different cell types, including endothelial cells.  
Gospodarowicz, in 1974, isolated two distinct protein forms:  the acidic fibroblast growth 
factor, FGF-1, and the basic fibroblast growth factor, FGF-2. Although it showed a high 
degree of sequence similarity, possessed a distinct act as mitogen (Gospodarowicz, 1974). 
The activity of these polypeptides is manifested as a result of the interaction with 2 receptors: 
a high affinity tyrosine kinase receptor (FGFR) and a low affinity one represented by 
proteoglycan heparan sulfate (HSPG) (Presta et al., 2005). 
FGF-2 attends angiogenic process stimulating, principally, the proliferation of endothelial 
cells. Moreover, this factor can stimulate the migration of macrophages and fibroblasts to the 
damaged area.  
Many solid tumours demonstrate increased expression of FGF-2 and its receptor including 
malignant melanoma (Becker et al.,1989), ovarian carcinoma (Crickard et al., 1994) and  
NSCLC (Takanami e al., 1996). bFGF and FGFR-1 expression in adenocarcinoma has been 
shown to correlate with microvessel density (Takanami et al.1997) although a more recent 
study has contradicted these findings (Gubbo et al., 1999).  
Angiopoietins 
Ang-1 and Ang-2 are secreted factors that mediate their effects by binding to the endothelial-
specific Tie-2 tyrosine kinase receptor (Davis et al., 1996). In vivo analysis has revealed that 
Ang-1 recruits periendothelial cells, whereas Ang-2 is presumed to destabilize blood vessels 
by interfering with constitutive Ang-1/Tie-2 signals in the vessel wall, leading to the 
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detachment of the perivascular cells and allowing the vessel endothelium to revert to a more 
plastic state of angiogenesis. Apparently conflicting publications report increased, decreased 
or unchanged expression levels of both Ang-1 and Ang-2 in a wide range of tumors (Tail et 
al., 2004). Angiopoietins are growth factors, that have a high affinity to the vascular 
endothelium (Gale et al., 1999). Although absolute levels of either Angs may increase or 
decrease, the ratio Ang-1:Ang-2 shift in favor of Ang-2. This implicates Ang-2 as a candidate 
for the angiogenic switch. 
Trasforming Growth Factor  
Trasforming Growth Factor is used to identify two classes of growth factors: TGF- and 
TGF-. TGF-polypeptides are produced by macrophages and cerebral cells; they are over-
expressed in some tumoral forms, they induce epithelium development and contribute  to the 
recovery of nervous tissue functionality after damage or neurodegenerative disorders (Fallon 
et al., 1990) 
Transforming growth factor beta form, instead, consists of three multifunctional isoforms 
which are able to regulate the proliferation and cell differentiation. Produced and released by 
various cell types, it plays a central role in tissue regeneration, in cell differentiation, in 
embryonic development and in the regulation of the inflammatory system. TGF- and TGF-
act, synergistically, to activate transforming cellular processes and to promote angiogenesis 
(Pepper,1997; Schreiber et al., 1986). TGF-effect on angiogenic process is due to 
recruitment and stimulation of macrophages and fibroblasts (Pepper, 1997); moreover, they 
stabilize neo-formed vessels, recalling smooth muscle cells and perycites (Darland et al., 
1999). 
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Platelet-derived growth factors  
PDGFs are growth factor that act by tyrosine kinase receptor  (PDGFRs). Studies of PDGFs 
and PDGFRs in animal development have revealed  roles for PDGFR- signaling in 
gastrulation and in the development of the cranial and cardiac neural crest, gonads, lung, 
intestine, skin, CNS, and skeleton. Similarly, roles for PDGFR-signaling have been 
established in blood vessel formation and early hematopoiesis.  
Endothelin 
There are, also, other endogenous factors which are able to regulate angiogenic process. 
Endothelin (ET) is part of the family of peptide, principally, secreted by endothelial cells; 
these molecules act through the interaction with two classes of receptors GRP, ETA-R and 
ETB-R (Nussdorfer et al.; 1999). ETs are formed by three isoform: ET-1, ET-2, ET-3; it was 
demonstrated that ET, in association with VEGF, have a clear pro-angiogenic activity 
(Matsuura et al.; 1998; Pedram et al.; 1997).  
Matrix Metallo-proteases  
MMPs consist in a family of at least 20 zinc-dependent endopeptidases, capable of degrading 
the extracellular matrix. They are known for their involvement in the release of apoptosis 
inducer and in the regulation of chemokines activity. MMPs, also, take part in various cellular 
events, the proliferation, migration, differentiation and survival. As modulators of 
extracellular microenvironment, they are essential for the various angiogenic stages: from the 
deposition to the destabilization of basal membrane, for direct effect on the components of the 
ECM (Chang et Werb, 2001). 
Produced by epithelial cells, by fibroblast  and by inflammatory mediators, MMPs are 
secreted in an inactive form and subsequently converted into the active form by proteases 
present in extracellular environment (Westermarck et al., 1999). 
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To guarantee tissue homeostasis, there is a control system of the proteolytic activity of MMP, 
which acts at the level of gene expression and  producing endogenous tissue inhibitors (t issue 
inhibitors metallo-proteases, TIMP). MMPs are involved in tissue remodeling not only in 
physiological processes, but there are several pathological conditions that present abnormal 
proteolytic system: cirrhosis, arthritis, development and tumor angiogenesis. 
Chemokines 
Chemokines are broad-range regulators that play important roles in inflammation and cancer 
(Keeley et al., 2008). They are divided into four families, based on structural properties and 
primary amino acid sequence, as CXC, CC, C or CX3C. CXC chemokines represent a family 
of homologue peptides exhibiting positive or negative activity on the control of angiogenesis. 
Angiostatic CXC chemokines have an important role against tumour development and 
diffusion. As these molecules also directly affect the tumour cells themselves, they may be, in 
addition, involved in adaptive/evasive resistance. Overexpression of CXCL4 (CXC 
chemokine ligand 4) and IP-10 (interferon-γ - inducible protein 10) blocks tumour progression 
and can also induce regression of metastasis.  
CXCL-8 and its receptors, CXCR1 and CXCR2, also, play an important role in angiogenic 
phenomenous and in tumoral development (Salcedo et al., 2000). 
 
 
 
 
 
 
 
 
27 
 
1.2.3 Inhibitors factors of angiogenesis 
The existence of angiogenic inhibitors was postulated by Folkman in 1971, but the real 
discovery of the first angiogenic inhibitor was due to Zetter and Folkman, in 1980; in these 
years they demonstrated that interferonwas able to inhibit endothelial cells migration, in 
reversible and dose-dependent manner. Since 1980 to 2005 Folkman and his colleagues, 
identified twelve angiogenic inhibitors: 
interferon platelet factor 4, angiostatic steroids, fumagallin, angiostatin, thalidomide, 2- 
metoxyestradiol; endostatin, ATC (Cleved Antithrombin III), 3-aminothalidomide, BDF-maf, 
caplostatin. 
Endogenous inhibitors of activated endothelial cell can be divided in:  
- Soluble mediators, as Trombospondin-1 (TPS-1), which is considerate the principal 
physiological inhibitor of vascular genesis being produced by normal cells. The over-
expression  of TSP-1 causes the inhibition of angiogenic process (Streit et al.; 1999). 
Other same inhibitors are Troponin I, INF-a, IL-12 and IL-4, retinoic acid; 
-  Proteic fragments as angiostatin and endostatin; the first, binds ATP synthetase 
interfering, in this way, with ATP production and inhibiting, consequently, cell growth 
(Moser et al.; 1999). It seems  that this fragment is involved in the inhibition 
endothelial cell migration and proliferation (Claesson-Welsh et al.; 1998). Endostatin 
inhibits endothelial cell proliferation in vitro and increases tumoral apoptosis (Liekens 
et al.; 2001). 
- Genetic factors as p53, which belonged to onco-suppressor family, molecules that 
encode for gene which block the uncontrolled proliferation of cells. Some studies have 
highlighted its involvement in the degradation process of inducible hypoxic factor 
(HIF-1), that favorites expression angiogenic activators (Ravi et al.; 2000). 
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Endogenous non- classical inhibitors are represented by: samatostatin, which inhibits cell 
growth and angiogenic process (Patel et al., 1999; Garcia de la Tore et al., 2002).  
Somatostatin receptor, SST2-R, mediates anti-angiogenic action of somatostatin directly 
involving the inhibition of cell proliferation (Danesi et al., 1997) and, indirectly, blocking the 
production of growth factors (Cascinu et al., 2001; Mentlein et al., 2001). 
 
1.3  Tumoral angiogenesis 
When the angiogenic balance shifts to pro-angiogenic factors, pathological angiogenesis, a 
process in which there is an uncontrolled growth of new blood vessels, starts. This event is 
typical of tumoral process/progression; in fact, when cancerous cells are established, they 
need oxygen and nutrients to allow the mass growth. Classic studies by Folkman showed that 
tumours cannot grow beyond 1-2 mm without the new blood vessels (Folkman, 1971). 
Oxygen and nutrients come from vessels and, for this reason, tumoral cells induce an 
environment in which there is a low concentration of oxygen and this event causes an 
increase, in this site, of HIF-1that transcript for some pro-angiogenic factors, such as 
VEGF, to unleash angiogenic process and formation of new blood vessels. Tumoral nascent 
blood vessels are structurally and functionally abnormal; they are  not organized like normal 
blood vessels and have an irregular diameter. Furthemore, the wall of these vessels is not 
formed by an uniform layer of endothelial cells, but by a mix of endothelial and tumoral cells.  
The abnormality of tumor blood vessels  (high disorder, tortuousness, swelling, and excessive  
branching) leads to chaos of blood flow, hypoxia, and  accumulation of acidic materials (Peng 
and Chen, 2009). The vascular wall presents numerous gaps, dilated inter-endothelial 
junctions and a discontinuous or absent basal membrane; all these features make the vessels 
particularly permeable. 
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                                        Fig.6: Structure of physiological vessel (A) and tumaral vessel (B) 
 
This idea of tumoral angiogenesis comes from the experiments of Folkman (1971); he 
implanted tumoral cells in the eyes of rabbits, and showed a production, by the side of 
tumoral cells, of growth factors able to induce the formation of a new vascular network, 
indispensable for the growth of tumors. Folkman tried to implant tumoral cells, also, in 
corneas, which, lacking in blood vessels, received nutrients by aqueous fluid contained in the 
anterior chamber. In these conditions, after a week, the tumor arose as a sleeper. Then, he 
implanted the same tumoural cells around the iris, a region rich in blood vessels, and he 
showed the trigger of angiogenic process. After these results Folkman believed that at the 
basis of angiogenic process there was  the production of Tumor Angiogenesis Factor (TAF). 
He, also, found a way to explicate why tumoral implants, in cornea and in iris, were so 
different. He concluded that, to have angiogenic process the presence of preexisted vessels in 
the proximity of the tumoral implant was necessary; in fact, tumoral cells implanting at 
distance major of 3 mm of blood preexisting vessels there was no presence of angiogenesis. 
On the basis of these results, it was supposed that tumoral cells producing TAF, were able to 
arrive at blood preexisting vessels and then got off angiogenic process. Folkman wanted to, 
also, demonstrate that tumoral cell in order to growth needed besides oxygen and nutrients, 
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also blood vessels, and in this way confirming his hypothesis. For this reason, he did an 
experiment in vitro in which tumoral cells had oxygen and all nutrients for their growth and 
survival. This proof highlighted the death of internal cells of tumor; this death was 
understandable as tumoral internal cells did not receive nutrients. 
On the basis of these data, tumor progression is characterized by two phases: 
 Avascular phase: oxygen and nutrients are guaranteed to the mass by the simple 
process of passive diffusion; 
 Vascular phase: hypoxic state of cells more distant from blood vessels stimulates the 
production of pro-angiogenic factors, responsible of the formation of new blood 
vessels. 
Following his studies, Folkman published in the „„New England Journal of Medicine‟‟ a 
hypothesis that tumor growth is angiogenesis dependent and that inhibition of angiogenesis 
could be therapeutic (Folkman, 1971).  
 
 
 
 
 
 
 
 
 
                               
 
 
 
 
                            Fig. 7: Scheme of the  all events that occurs in tumoral angiogenesis 
 
 
 
 
31 
 
1.3.1 Antiangiogenic therapy in cancer treatment 
Knowledge about molecular mechanism of formation, growth and progression of cancer, had 
allowed “focused therapy” to be produced. These therapies are based on the use of “intelligent 
drugs” that, unlike the standard anti-cancer drugs, act, preferentially on tumoral cells.  
Standard chemotherapy, in fact, uses substances that act inducing cell death interfering with 
replication  mechanism of the same cells. One of the negative aspects of the use of classical 
chemotherapic drug is their capacity to act not only on tumoral cells, but, also, on normal cells 
such as blood cells or the cells of gastric mucosa or cells of hair bulbs. In fact, for this side 
effect, patients are affected by hair loss, nausea and vomit, blood disorder like anemia. 
By using “intelligent drugs” many side effects are reduced, given that these drugs act with a 
focused approach on one or more events that promote tumoral progression. In particular, these 
molecules are able to act reducing tumoral cells proliferation, obstructing angiogenic process, 
promoting tumoral cells apoptosis, stimulating immune system to attack tumoral cells.  
Anti-angiogenic therapy shoots tumoral cell death for the absence of oxygen and nutrients, 
normally transported by blood vessels. Moreover, limiting supply of vessels in tumoral mass, 
the migration of tumoral cells to other organs (tumoral metastasis) it is, also, limited. 
Anti-angiogenic treatments, actually approved in cancer therapy, are based on the use of: 
 Monoclonal antibodies; 
 Tyrosine kynase inhibitors (TKI); 
 mTOR (mechanistic target of ripamycin) inhibitors 
Monoclonal antibodies 
Monoclonal antibody therapy is based on its interaction with specific growth factors and their 
related receptors. One of the first drugs used with this mechanism was Avastin. Avastin, 
also known as Bevacizumab, is able to bind VEGF blocking its interaction with receptors 
presents on the surface of endothelial cells. The absence of VEGF is translated in a decrease 
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of endothelial cells migration and proliferation. The major success of this therapy was 
obtained in the treatment of lung cancer, which is the most common malignancy and the 
leading cause of cancer death worldwide (Parkin et al., 2002;  Jemal et al., 2005). It was, in 
fact, estimated that in 2011 over 221.130 new cases of lung cancer were diagnosed and over 
of 156.940 people had died due to this pathology.  
FDA has approved the use of Avastin for the treatment of non small cell lung carcinoma 
(NSCLC). Clinical studies have demonstrated that, in patients affected of NSCLC, the 
treatment with Avastin, associated with common chemotherapics drugs, has prolonged the 
period of survival of patients by about two months. It has gone from a time of 10.3 months in 
case of treatment with only chemotherapic drugs, to 12.3 months in patients treated with 
chemotherapy associated to anti-angiogenic agents.  
The most common side effect of all monoclonal antibodies is an allergic reaction to the drug: 
fever, changes in blood pressure, feeling sick and breathlessness, nausea and diarrhea.  
Tyrosine kinase inhibitors 
Another therapeutic strategy in phase of study, is proposed by tyrosine kinase inhibitors. This 
strategy acts not only on VEGF, but also on epidermal growth factor (EGF), that linking a 
tyrosine kinase receptor (EGFR), stimulates endothelial cell proliferation, too. Tyrosine 
kinase receptors are membrane receptors, that have extracellular domain, thro ugh which link 
the ligand, and citoplasmatic domain, that has kinasic activity. This receptor is presented,  
initially, as a monomer having a inactive tyrosine kinase domain; as a result of ligand binding, 
the receptor occurs as a dimer in which the cytosplasmatic domain is active. Each monomer 
phosphorylates the other on a tyrosine residue and the kinase is able to phosphorylate other 
intracellular proteins thereby initiating the signal transduction.  
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Tarceva (Erlotinib) inhibits EGFR binding intracellular portion, that normally, interact with 
ATP; in this way is blocked kinase activity, due to the lack of signal, and cell proliferation 
stops. 
mTOR inhibitors  
mTOR is a serine/threonine kinase-protein that regulates protein synthesis, cell proliferation 
and survival in response to hormones, stress and growth factors. mTOR is a catalytic subunit 
of two complex as mTORC1 and mTORC2. Activated mTORC1 up-regulates protein 
synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. 
This includes phosphorylation of EIF4 EBP1 and release of its inhibition toward the 
elongation of initiation factor 4E (eiF4E). These kinases mediate cellular responses to stresses 
such as DNA damage and nutrient deprivation. This protein acts as the target for the cell-
cycle arrest and immunosuppressive effects of the FKBP12-rapamycin complex.  
Afinitor (Everolimus) is an mTOR inhibitor; it acts by a type of targeted therapy that blocks 
FKBP12, blocking, consequently, mTOR activity. By blocking this protein, Everolimus can 
stop cancer cells from growing. Everolimus may also prevent tumors from developing new 
blood vessels, which would help to limit their growth. This drug is, actually, used to treat 
advanced kidney cancer, advanced breast cancer, a rare type of brain tumor (subependymal 
giant cell astrocytoma), and a rare type of pancreatic cancer (pancreatic neuroendocrine 
tumor). 
 
 
 
 
 
 
34 
 
1.4 FDA approved drugs in antiangiogenic therapy 
Recently, many drugs, which explicate their action by an anti-angiogenic mechanism, used to 
treat cancer were approved. In particular, FDA  approved many monoclonal antibod ies which 
have different target as reported in table 3.  
 
    
Table 3: List of approved monoclonal antibodies by FDA 
 
Moreover, other small molecules drug were approved by FDA in anti-angiogenic cancer 
therapy as reported belowe: 
 
Targets for s mall-molecule drugs in anti-angiogenic therapy 
Molecular targets                          Small-molecule drugs                                      Current status  
Growth factor  receptors                      Gefitin ib/Iressa

   FDA approved (Cohen et al.; 2003) 
                                                             Lapatinib/Tykerb

   FDA approved (Moy et al.; 2007) 
                                                             Erlotinib/Tarceva

  FDA approved (Cohen et al.; 2005) 
Multiple growth factor receptors         Imat inib/Glivec

   FDA approved (Habeck et al.; 2002) 
                                                             Sunitin ib/Sutent

   FDA approved (Rock et al.; 2007) 
                                                             Sorafen ib/Nexavar

   FDA approved (Land et al.;2008)                                                                                                                                                                                                                                                            
                                                                                                                                        (Wu et al, 2008) 
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Although these drugs have reported satisfying effects in cancer treatment, the principal 
limitation about the large use of these molecules is linked to its higher costs and its high 
immunization. Therefore, several researchers are focused on the identification of other 
molecules able to treat angiogenesis, but at lower costs.  
In this contest, the idea of the present thesis was to test, in cancer treatment, marijuana 
derivates for its well know anti-tumoral and anti-angiogenic proprieties.  
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2.  Cannabinoids 
 
2.1 Cannabis Sativa L.: a brief history 
Cannabis is a flower plant and its history, in pharmacological environment, goes back to 
ancient times; documents that certify its use only date back to later times such as that of the 
great Chinese empire Chen Nung, about 5000 years ago. In this period, in fact, a herbarium 
highlighting the medicinal properties of many plants even including hemp was published. It 
was recommended for malaria, constipation, pain, "female problems" and in association with 
wine and resin was indicated as an analgesic during surgery. Even though other civilizations 
have released evidence on the use of this plant , such as the Egyptians, the Assyrians and the 
Indians. The most important text dated back to the first century BC and belongs to the Greeks 
and Romans communites. In fact, a Greek doctor, described in Pedanius Dioscorides 
approximately 600 medicinal plants of the Middle East including the Cannabis which was 
reported to have anti- inflammatory and analgesic effect.  
The structure of the main psychoactive ingredient 9-tetrahydrocannabinol (9-THC) was not 
elucidated until 1964 (Gaoni, Mechoulam, 1964) and it was generally assumed that the high 
lipophilicity of this compound was the cause of a lot of its pharmacological effects. In 1988, 
Howlett (Howlett, 2004) and his colleagues identified the specific 9-THC binding site in the 
brain and then, Matsuda (Matsuda et al., 1990) characterized the first cannabinoid receptor, 
CB1, from a series of orphan G-protein coupled receptor. Mechoulam‟s (Devane et al., 1992) 
hypothesis was that it was not possible that THC binds a receptor free from endogen 
biological activity; in fact, he supposed that exists necessarily an endogenous compound able 
to act and to promote a biological response of CB1. Devane and Mechoulam‟s work led up to 
the discovery of an endogenous THC-like molecule, called Anandamide (N-
arachidonoylethanolamine; AEA) from „ananda‟, the sanskrit word for „bliss‟(Devane et al., 
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1992), was isolated and found to activate CB receptors, thus mimicking the psychotropic 
effects of THC (Mechoulam et al.,2002). In a few years other endogenous agonists of CB1 
receptors were characterized, and were collectively called „endocannabinoids‟ (Di Marzo,  
1998). Munro (Munro et al., 1993), in 1993, identified a second cannabinoid receptor, CB2, in 
HL60 (human promyelocyties leuchemic 60) cells line; this receptor had the ability to interact 
with anandamide in a manner minor compared to the CB1 receptors, and its localization was 
identified prevailing at the level of peripheral organs as spleen and thymus. These 
informationled to the identification, by a Japanese group, in 1995,  of a second cannabinoid 
ligand, 2-arachydonoil glycerol (2-AG) (Mechoulam et al., 1995) and, also, this compound 
had major affinity to CB1 and CB2 receptor then AEA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
      
                        Fig. 8: Cannabis Sativa L. 
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2.2 Endocannabinoids System (ECS) 
The Endocannabinoid System (ECS) is a complex lipidic transmission net localized in human 
system both in central and peripheral system. To this day, five endogenous ligands, able to 
interact with cannabinoid‟s receptors, have been discovered: AEA, 2-AG, 2-
Arachidonoilglycerol ether (2-AGE), virodamin and N-arachidonoildopamin (Rodriguez de 
Fonseca et al., 2005). All of these compounds have a common structure, a portion of 
arachidonyl glycerol, that is condenced with an ethanol-amine, glycerol or dopamine. 
 
 
  Fig 9: Chemical structure of endocannabinoids 
 
 Other ligands of cannabinoid receptors can be divided into: classical, non-classical and 
aminoalchylindols (Howlett, 2002). Classic derivatives includes benzopyraminic derivates, 
that are both compounds derives by Cannbis Sativa (fitocannabinoids) and their synthetic 
analogues. An example is 9-THC, 8-THC, and cannabidiol. Moreover, synthetic anologues 
are: 11-hydroxy-∆8 - THC-dimethylheptyl (HU-210), JWH-133, L-759633, L-nantradol and 
desacetyl- l-nantradol. Non classical compounds consist of bicycles and tricycles analogues 
of 9-THC that link a pyranic ring; examples of these are: CP55940, CP47497 and HU-308. 
Class of aminoalchylindols includes compounds with a different structures of other 
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cannabinoids: WIN5521-2, AM1241, JWH- 015, BML190. (Howlett 2002; Pertwee, 1999; 
Porter, 2002). 
AEA and 2-AG are the most important endocannabinoids both for their abundance in human 
body and for their capacity to bind cannabinoid receptor (AEA Ki CB1 = 32 nM, Ki CB2 = 
1930; 2-AG Ki CB1 = 472 nM, Ki CB2 = 1400). 
These two mediators are biosynthesized by different process (Sugiura et al., 2002), but both 
need Ca++ for their synthesis. 
For the synthesis of AEA there are two different and independent strategy:  
- formation of AEA started by arachidonyl acid and ethanolamine; this reaction is not 
specific and the ethanolamine react with several fatty acid presents at cellular level 
(Sugiura et al., 1996);  
- formation of AEA started with the formation of N-
arachidonoylphosphatydilethanolamine (NAPE) by a mechanism via transacylase, that 
needs Ca++, and, then, by a NAPE-phospholipase D there are a release of N-
acylethanolamine (NAE) and phosphatidic acid. NAPE synthesis is thought to occur 
through the action of an N-acyl transferase that catalyzes an exchange reaction 
between the sn-1 position of donor phospholipids and the primary amine of 
phosphatidylethanolamine (PE).  
The biosynthesis of 2-AG is more complicated; several pathways are identified for the 
synthesis of this compound but no one is favoured over the others. This endocannabinoid is 
most frequently synthesized through the hydrolysis of phosphatidylinositol-4,5-bisphosphate 
(PIP2) with arachidonic acid (AA) on the sn-2 position to diacylglycerol (DAG) by 
phospholipase C-β (PLC-β). The DAG is then hydrolyzed to 2-AG by diacylglycerol lipase 
(DAGL)  (Stella et al., 1997; Bisogno et al., 1999; Bisogno et al., 2003).  
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AEA and 2-AG are transported by a common molecule: AMT, Anandamide member 
transporter, while their degradation is mediated by different enzyme.  
AEA is metabolized by fatty acid amide hydrolase (FAAH), that is an enzyme which divide 
AEA in AA and ethanolamide. FAAH is an enzyme of serin-hydrolase family and it is 
composed by 579 amino acids of which Ser-241 is the catalytic nucleophilic site (Cravatt et 
al., 1996). This hydrolase metabolizes AEA, but it can, also, promote the synthesis of AEA 
despite this reaction needs a high quantity of that endocannabinoids (Schmid et al., 1998). 
AEA is, also, metabolized by another amino-hydrolase that acts in an acid environment 
instead of an alcalin environment in which acts FAAH (Ueda et al., 1999).  
The main enzyme responsible for 2-AG hydrolysis is believed to be monoglyceride lipase 
(MAGL; also called monoacylglycerol lipase) (Drin et al., 2002; Saario et al., 2004). MAGL 
is a serine hydrolase with three catalytic essential amino acid residues: Ser-122, Asp-239 and 
His-269 (Karlsson et al., 1997). MAGL has been cloned from both human adipocytes and rat 
brain, it consists of 303 amino acids and has a molecular weight of ~33 kDa (Karlsson et al., 
2001). This enzyme degrades 2-AG in AA and glycerol; MAGL is not the only enzyme 
degrading 2-AG, in fact, other metabolic pathways have been discovered. One of these, is the 
pathway that consisting in the degradation of 2-AG in 2-arachidonyl LPA; this way allows the 
recycling of 2-AG to form glycerol phospholipids, as phosphor- inositols (Shire et al., 1999). 
Another pathway outlook the degradation of both endocannabinoid by COX-2 in 
prostaglandins due to the fragment of arachydonoyl acid in their structure (Kozak et al., 
2003). 
After AEA and 2-AG production, these mediators are not preserved in vesicles but they are 
synthesized “on demand” by post-synaptic cells and function as retrograde signaling 
molecules, diffusing back across the synapse to bind with pre-synaptic CB1 receptors, which 
reduces synaptic transmitter release (Stella et al., 1997). In the central nervous system, 
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endocannabinoids act as neuromodulators or retrograde messengers (MacDonald and 
Vaughan, 2001) which inhibit the release of various neurotransmitters (Schlicker and 
Kathmann, 2001); in the peripheral and neural tissues, they modulated the effects of proteins 
and nuclear factors involved in cell proliferation, differentiation and apoptosis, as paracrine or 
autocrine mediators. 
 
    
 
 
Fig.10: Biosynthesis, action and degradation of AEA and 2-AG. 
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Two receptor were cloned for cannabinoids: CB1 and CB2; both receptors belong to the family 
of the „seven trans-membrane spanning receptors‟, and are coupled to G proteins, particularly 
those of the Gi/Go family (McAllister and Glass 2002; Mechoulam et al., 2002; Di Marzo, 
1998).  
CB1 receptors are, mainly, localized in nervous system, bone marrow, but they are, also, in 
peripheral system as in endocrine and salivary glands, heart, gastrointestinal system. They are 
expressed in nervous system, principally, in that area responsible of movement and 
modulation of pain. Signal transduction pathways regulated by CB receptor-coupled G 
proteins include the inhibition of adenylyl cyclase, the regulation of ionic currents (inhibition 
of voltage-gated L-, N- and P/Q-type Ca++ channels, activation of K+ channels), the activation 
of focal adhesion kinase (FAK), of mitogen-activated protein kinase (MAPK), of cytosolic 
phospholipase A2 and of nitric oxide synthase (NOS). Central and peripheral CB1 receptors 
modulate appetite and energy metabolism, respectively. CNS receptors are expressed on 
hypothalamic and limbic neurons; those in the periphery exist on adipocytes, skeletal muscle 
cells and hepatocytes. Activation of peripheral CB1 receptors promotes fat deposition and 
insulin resistance (Tibirica, 2010). 
CB2 receptors are, principally, localized on immune cells (mast cells, macrophages, B cells, T 
lymphocytes), spleen and tonsils. CB2 is implicated in immune regulation Unlike CB1 
receptor, there is a considerable level of sequence variation CB2 receptor among human, rat 
and mouse species, particularly when comparing rat and human sequences. There is 81% 
amino acid identity between rat and human CB2, as compared to 93% amino acid identity 
between rat and mouse CB2 (Griffin et al., 2000). Located on antigen-presenting cells, it 
influences their cytokine profile (Tanasescu, 2010). Its expression on microglia is upregulated 
in the dorsal root ganglia and spinal cord following sciatic nerve injury. It also may be 
expressed on neurons (Atwood et Mackie, 2010). 
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Recent studies have demonstrated that CB2 is expressed also within the CNS and that this 
expression occurs during various states of inflammation (Nunezet al., 2004; Cabral et al., 
2005; Fernandez-Ruizvet al., 2007). This expression of CB2 has been localized primarily to 
microglia, the resident macrophages of the CNS. CB2 expression is detected in these cells 
upon activation by various insults and stimuli, but measurable levels of CB2 expression 
cannot be detected in resident, un-stimulated microglia. In addition, during neuro-
inflammation, infiltrating immunocytes from peripheral non-neuronal sites that influx into the 
brain as a result of breakdown of the blood-brain barrier (BBB), contribute to the overall 
expression of CB2 (Schatz et al., 1997; Ramirez et al., 2005). 
Evidence has emerged that in addition to CB1 and CB2 receptors there are other molecular 
targets through which the endocannabinoids might induce a biological activity. In particular, a 
target of AEA which is attracting great interest is the type 1 vanilloid receptor (VR1), a „six 
trans-membrane spanning protein‟ with intracellular N- and C-terminals and a pore loop 
between the fifth and sixth transmembrane helices (Jordt and Julius, 2002). It is, also, 
demonstrated that AEA might function as a modulator of orphan receptor, GPR55.  
 
                      
                            Fig. 11:Molecular structure of CB1 and CB2 receptors 
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2.3 Patho-physiological action of CBs 
Several scientific works  show the involvement of endocannabinoid system in various 
pathological conditions (Di Marzo, 2006). One of the first uses of Cannabis was as a 
painkiller; in fact, cannabinoid receptors are, abundantly, expressed in areas that are involved 
in the transmission and modulation of nociceptive stimuli, such as rostral ventromedial 
medulla (RVM), spinal cord dorsal horn, periaqueductal grey (PAG) (Lichtman et al., 1996). 
Cannabinoids, either natural, endogenous or synthetic, produce anti-nociceptive effects 
primarily through the activation of CB1 receptors which, in these sites, are generally located 
presynaptically and so their activation inhibit the release of neurotrasmitters (Millan, 2002).  
On the other hand, it is, also, conceivable that the analgesic/antinociceptive effect is due to the 
inhibition of the release of several mediators of pain or inflammation through the activation of 
CB2 peripheral receptors (Walker et al., 2002; Calignano et al., 1998). CB2 receptors have 
been related, traditionally, to the peripheral effects of cannabinoids (mainly related to 
modulation of the immunologic responses), but recent findings suggest that they also 
contribute to antinociception by inhibiting the release of proinflammatory factors by non-
neuronal cells located near nociceptive neuron terminals. In fact, CB2 receptors are expressed 
in several types of inflammatory and immunocompetent cells and their activation generates an 
antinociceptive response in situations of inflammatory hyperalgesia and neuropathic pain 
(Ibrahim et al., 2003; Valenzano et al., 2004). On the other hand, CB1 receptors are also 
present in mast cells and may participate in some anti- inflammatory effects through inibition  
of their degranulation (Small-Howard et al., 2005).  
It is, also, well know, that the use of cannabis increases the appetite. Several studies, have 
shown that both AEA and 2-AG, binding CB1 receptor, directly, induce an increase in food 
intake (Kirkham et al., 2002). Treatment with CB1 antagonists has shown that reduce body 
weight, and also it lowers the triglyceride concentration in the blood, increasing the 
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concentration of HDL in spite of LDL, decreased glucose tolerance by reducing the incidence 
of the metabolic syndrome (Despreset al., 2005). 
Cannabinoids may also modulate intestinal motility in vivo through the activation of CB1 
receptors, thus its pharmacological modulation through the use of agonists could be useful for 
decreasing gut motility in intestinal bowel diseases, whereas its inhibition by antagonists can 
increase motility, acting so as a prokinetic (Aviello et al., 2008). 
Phytocannabinoids resulted neuroprotective in several models of neurodegeneration and this 
effect has been correlated with their ability to reduce gliosis and neuroinflammation (Iuvone 
et al., 2004; Esposito et al., 2011) effects followed by an amelioration of mnemonic and 
motor performances in behavioural studies executed on in vivo models of Alzheimer‟s disease 
and Parkinson‟s disease.  
 
2.4 Cannabinoid drugs in therapy 
Medicines that activate cannabinoid CB1 and CB2 receptor are already in the clinic. These are 
Cesamet® (Nabilone), Marinol® (Dronabinol; 9-tetrahydrocannabinol) and Sativex® (9-
tetrahydrocannabinol with cannabidiol).  
The first two of these medicines can be prescribed to reduce chemotherapy-induced nausea 
and vomiting. Marinol® can also be prescribed to stimulate appetite for AIDS patients, while 
Sativex® is prescribed for the symptomatic relief of neuropathic pain in adults with multiple 
sclerosis and as an adjunctive analgesic treatment for adult patients with advanced cancer 
(Pertwee,2009). Sativex® is a cannabis extract and contains about the same amount of THC 
and cannabidiol (CBD). 
Another drug, based on cannabinoid ingredients, is Rimonabant,Acomplia®; it was the first in 
a new class of therapeutic agents called CB1 blockers. Acomplia
® was studied for use in the 
treatment of obesity and related conditions and it acts by selectively blocking CB1 receptors 
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found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, 
including adipose tissue, the liver, gastrointestinal tract and muscle (Pagotto et al., 2005).  
However, in clinical studies, Acomplia® was has been shown to improve a wide array of 
cardiometabolic risk factors as well as promoting sustained weight loss (Di Marzo, 2001; 
Despres et al., 2005), and, in 2009, Acomplia® was officially withdrawn by the European 
Medicines Agency (EMEA) due to the risks of dangerous psychological side effects, induce 
to suicid. 
 
2.5 Cannabinoids and cancer 
Many studies produced information about anticancer effect of cannabinoid-related drugs. 
Cannabinoids can play an important role in the palliation of pain, nausea, vomiting, and 
appetite for cancer patients. Plant-derived, synthetic, and endogenous cannabinoids, also, 
modulate tumour growth, apoptosis, migration and neo angiogenesis in various types of 
cancer (Bifulco and Di Marzo, 2002; Guzman et al., 2002) as prostate, breast, tyrode, 
leukemia and colon carcinoma.  
Initially, it was  shown a different expression of CB1 and CB2 receptors in normal and 
malignant cells. In fact, CB1 is up-regulated in mantle cell lymphoma and in prostate cancer 
cells, while, CB2 expression is increased in breast cancer (Caffarel et al., 2006). It was, also, 
found that CB2 receptors increased in gliomas and the expression levels positively correlated 
with malignancy. Also, AEA and 2-AG were up-regulated in cancer; both these 
endocannabinoids were increased in their expression in human colorectal adenomatous polyps 
compared to normal mucosa (Ligresti et al., 2005). AEA was, also, overexpressed in prostate 
cancer, endometrial sarcoma, thigh histiocytoma (Schim et al.,2002) and in glioblastoma 
(Peterson et al., 2005). 2-AG was, on the other hands, increased in its expression in human 
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pituitary adenomas compared to normal pituitary glands (Pagotto et al.,2001), in meningiomas 
and in lung cancer (Peterson et al., 2005).  
Despite that, the use of cannabinoid has been limited for its psychotropic effects; in 1975, for 
the first time, Munson and his collaborators showed anti- tumor effect of cannabinoids. They 
showed that 9-THC and 8-THC inhibited  Lewis Lung adenocarcinoma cells growth both in 
vitro and in vivo. Then, other studies demonstrated anti-proliferative, anti-metastatic, anti-
angiogenic and anti-apoptosic effect of cannabinoids in various cancer type (lung, 
glioma,thyrod, lymphoma, skin, pancreas, uterus, breast and prostate cancer) using in vitro 
and in vivo tumor models (Bergman et al.,  2008; Godlewski et al., 2013). In 2002, a clinical 
study about9- THC, its safety profile and its anti- tumoral activity in nine patients affect of 
neuroblastomas, an aggressive brain tumor, was approved in Spain. This study demonstrated 
the safety of intracranic administration of 9-THC and the reduction of tumoural growth; this 
effect was due to a reduction of proliferation and an increase of apoptosis, inducted by 9- 
THC, in cancer cells. On the basis of these results, a new approach of cancer treatment is 
evaluated. In fact, in addition to this information, many scientific papers have been published 
about the involvement of Cannabinoid system in cancer disease. 
Various cannabinoids, especially anandamide and THC, promote apoptosis of astrocytoma, 
glioma, neuroblastoma and pheochromocytoma cultured cells with a pathway involving 
cannabinoid receptors (Guzman, 2003; Goncharov et al, 2005; Velasco et al, 2007).  
After interaction with the cannabinoid receptors, their ligand activate different signaling 
pathways, which can be involved in their anti-proliferative effects as p38, MAPK and c-Jun 
N-terminal kinase (JNK) activation, increased synthesis of pro-apoptotic sphingolipid 
ceramide and other stress-related genes expressed in the endoplasmic reticulum (Diaz-
Laviada e Ruiz-Llorente, 2005). Ceramide, the central molecule of sphingolipid metabolism, 
generally average anti-proliferative responses, such as inhibition of cell growth, induction of 
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apoptosis and/or modulation of senescence (Saddoughi et al, 2008). Several therapeutic agents 
that induce apoptosis in ceramide-dependent cancer cells existed, and a number of enzymes 
involved in the metabolism of ceramide are starting to be recognized as potential targets for 
cancer therapy (Savtchouk et al, 2007; Carpinteiro et al, 2008). Recently, researches have 
shown that cannabinoids induce the accumulation of ceramide in tumor cells, that is linked to 
the pro-apoptotic effect of cannabinoids in cancer cells (Guzman et al, 2001; Velasco et al, 
2005). 
Finally, cannabinoids regulate cell survival pathways, modifying several signaling that are 
involved in tumoral cell growth and survival (Bifulco et al., 2008). The suggested mechanism 
underlying these effects, are complex specific, dependent by cancer type and include: 
- induction of apoptosis in tumoural cells; 
- anti-proliferative action by suppression of many mitogen signal; 
- anti-metastatic and anti-proliferative action by inhibition of angiogenic process.     
 
                                                                                                                                                                                     
 
 
 
    
 
 
   
 
 
 
 
 
 
                                 Fig. 12: Inhibition mechanism of tumoral growth by cannabinoids 
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2.6 Cannabinoids and angiogenesis 
Recently, in addition to their anti-proliferative and pro-apoptotic effects, it has been shown 
that cannabinoids can affect other important processes in tumourigenesis, in particular 
angiogenesis. 
In fact, another  mechanisms involved in the pharmacological actions of cannabinoids during  
cancer is related to the inhibition of angiogenic process, which plays a key role in tumor 
growth. Numerous evidence suggests that antitumour effect of cannabinoid-related drugs 
could be, at least in part, ascribed to inhibition of tumour neoangiogenesis in animal models. 
Many cannabinoids, such as WIN-55,212-2, HU-210, JWH133 and THC, inhibit, in vitro, the 
survival of human umbilical vein endothelial cells (HUVEC) and their migration during 
angiogenetic process (Blazquez et al., 2003). Treatment with these cannabinoids reduces 
vascular density in experimental tumors (Blázquez et al., 2003; 2006; Casanova et al., 2003; 
Portella et al., 2003; Preet et al., 2008). It is ,also, suggested, that, anti-angigenic propriety of 
cannabinoids might be due to the reduction of the expression of several pro-angiogenic 
factors. Particularly, a lot of study demonstrated that VEGF expression was strongly 
influenced by cannabinoids; in fact, nude mice treated with tyroide cell Kras-transformed, 
have demonstrated a decrease of VEGF and VEGFR1 levels  (Rak et al., 1995; Casanova et 
al., 2002) after treatment with Met-fluoro-anandamide (Met-F-AEA), a metabolic analogue of 
AEA. Anti-metastatic and anti-angiogenic effects are, also, ascribed to THC in non small cells 
lung cancer (NSCLC); in fact, after treatment with THC, lung cancer cells showed a minor 
expression of VEGF. In 2004, Blazquez, through cDNA arrays, demonstrated that JWH133, a 
full agonist of CB2 receptor, was responsible of a reduced expression of VEGFA, VEGFB and 
hypoxic inducible factor 1 (HIF-1) in glioma in mice. In 2003, Casanova showed that 
JWH133 and WIN-55,212-22 were able to reduce mRNA levels and EGFR auto-
phosphorilations, in skin tumors. In the same study, cannabinoids reduced the expression of 
50 
 
Ang-2 and PlGF. Treatment with WIN-55,212-2 or JWH- 133 caused impairment of tumor 
vascularization in skin cancer (Blazquez et al.; 2006). JWH133 is, also, able to reduce Ang-2 
expression in gliomas and astrocytomas.  
Cannbinoids  exerts their anti-angiogenic effect not only on growth factors but also on 
proteolytic enzymes involved into matrix remodelling, such as MMPs. It is demonstrated that 
MMP-2 is down-regulated by THC in human tumoral samples of glioblastoma. The 
expression of this enzyme is also decrease, in vitro, by THC and met-AEA in uterus cancer 
and, in vivo, by JWH133 in xenograph models of gliomas. CBD induced endothelial cell 
cytostasis without inducing apoptosis, inhibited endothelial cell migration, invasion and 
sprouting in vitro and inhibited angiogenesis in vivo. These effects were associated with a 
down-modulation of several molecules associated with angiogenesis, including MMP-2 and 
MMP-9, ET-1, platelet-derived growth factor-AA (PDGF-AA) and chemokine (c-x-c motif) 
ligand 16 (CXCL16) (Massi et al., 2008). Finally, Pisanti  and his colleagues, in 2007, 
demonstrated an inhibition of MMP-2 in endothelial cells incubated with Met-F-AEA. On the 
contrary, the influence that cannabinoids have on anti-angiogenic factors, such as tissutal 
inhibitors of MMPs (TIMPs) is, rather controversial. There are few evidences that the 
treatment with THC reduces the expression of TIMP in human cell line of glioma  (Blazquez 
et al., 2008), while CBD inhibits invasion of A549 cells both in vitro and in vivo, in lung 
cancer,  that was accompanied by upregulation of tissue inhibitor of matrix metalloproteinase-
1 (TIMP-1) (Massi et al.; 2008). 
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                                                  Fig. 13: Inhibition mechanism of angiogenis by cannabinoids 
 
 
In addition to the anti-angiogenic effects of CBs in tumor, several evidences suggest that CBs 
are able to control not only the angiogenic process associated to tumoral conditions. In fact, 
cannabinoids may prevent, at least in part, granuloma-associated angiogenesis, controlling 
mast cells function (De Filippis et al., 2008). Chronic inflammatory conditions, such as 
granulomas, are associated with angiogenesis; selective cannabinoid receptor agonists in a 
model of angiogenesis-dependent granuloma formation induced by λ-carrageenin in rats, 
exhibited antiangiogenic properties, in fact it was demonstrated that these cannabnomimetic 
compound were able to decrease neovascularization in the granulomas (De Filippis et al., 
2008). 
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3. Material and methods 
 
3.1 Animal models 
3.1.1 Animals 
Female mice (6-8 weeks) C57BL/6 were obtained from Charles River (Wilmington, 
MA,USA) and used for the study. We, also, used female mice (6-8 weeks) CB2 KO obtained 
from Charles River. Animals were provided with food and water ad libitum. The light cycle 
was automatically controlled (on 07 h 00 min; off 19 h 00 min) and the room temperature 
thermostatically regulated to 22±1 °C with 60±5% humidity. Prior to the experiments, 
animals were housed in these conditions for 3–4 days to become acclimatized. 
   
                                             
                                              Fig.14: C57BL/6 mouse 
 
 
3.1.2 Experimental protocol 
The tumour model we have used involves the induction of lung carcinoma in mice; briefly, 
Lewis Lung Carcinoma cells (LLC1; 2.5X105), that have a high tropism for the lung, were 
intravenously injected in C57BL/6 mice (Sorrentino et al., 2010). Animal model of lung 
carcinoma will performed in collaboration with the group of Prof. Aldo Pinto, University of 
Salerno, that possess a demonstrated expertise in the field.  
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JWH 133 (0.5, 1, 5 μg/mouse), a CB2 full agonist, and JZL184, a MAGL inhibitor (5, 10, 20 
μg/mouse), from 13th to 17th day after cell implant, were intraperitoneally administered daily.  
At the 17th day the mice were sacrificed and the left lung lobes were fixed in OCT medium 
and the 7-μm cryosections cutted were used for immunoistological analysis to measure the 
tumour burden, while the right lung lobes were homogenized for biochemical analysis to 
evaluated angiogenesis.   
 
3.2 Drug 
The compounds that we used are: 
(6aR,10aR)-3-(1,1-Dimethylbutyl)-6a, 7, 10, 10 a-tetrahydro-6, 6, 9- trimethyl-6H-
dibenzo[b,d]pyran (JWH133 in Tocrisolve™ 100) (TOCRIS, Ellisville MO): a potent 
CB2 selective agonist (Ki = 3.4 nM),  dissolved in water-soluble emulsion Tocrisolve
TM100 
composed of a 1:4 ratio of soya oil/water that is emulsified with the block co-polymer 
Pluronic F68. The cannabinoid is incorporated with the emulsion as part of a specialized 
innovative production process. The soya oil forms a coating around the cannabinoid molecule, 
and the block co-polymer is added to stabilize the emulsion, preventing the lipid droplets 
from coalescing (merging) in the surrounding water. JWH133 is, approximately,  200-fold 
selective over CB1 receptors. 
4- nitrophenyl-4-(dibenzo [d] [1,3] dioxol–5–yl (hydroxy) methyl) piperidine-1- carboxylate 
(JZL184, TOCRIS, Ellisville MO): a potent and selective monoacylglycerol lipase (MAGL) 
inhibitor. Blocks hydrolysis of the endocannabinoid 2-arachidonyl glycerol (2-AG). JZL184 
was dissolved in DMSO, obtained a stock solution and then, by serial dilutions, we used the 
appropriated concentration. 
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3.3 Cell culture 
3.3.1 Lewis Lung carcinoma cells 
Lewis Lung carcinoma cells (LLC1) (ATCC® CRL-1642™) were cultured in DMEM 
containing 10% FBS, L-glutamine (2 mM), penicillin (100 U/mL), streptomycin (100 g/ml) 
in an atmosphere of 5% CO2 at 37 °C. Cells seeded in 96 multiwell plates (1.5X10
5/well) 
were treated with JWH133 (dissolved in ethanol) 10-9, 10-8, 10-7, 10-6 M. After 24 hours 
incubation time, cells were subjected to different assay to evaluate viability and proliferation.  
                             
                                                                              
                                                          Fig.15: Lewis lung carcinoma cells 
 
 
3.3.2  Cell Functionality Assay 
To determinate cells functionality, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-
Formazan Assay (MTT assay) was performed. Cells were plated at the density of 
(1.5X105/well), left to adhere at 37 °C, and then treated as described previously. After 24-h 
incubation time, 25μl of 5g/L 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium solution 
were added to the cells. Cells were incubated for an additional 3 h at 37 °C before being 
lysed, and then dark blue crystals were solubilized with 100 μl of a 50% N,Ndimethyl 
formamide/20% sodium dodecyl sulfate solution with an adjusted pH of 4.5. Optical density 
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(OD) was measured with a spectrophotometer (Titertek Multiskan MCC/340; Titertek 
Instruments, Huntsville, AL) equipped with a 620-nm filter.  
 
3.3.3 Cell Proliferation Assay 
To determine the effect of treatment of JWH133 on LLC1 cellular proliferation, Cell 
Proliferation ELISA BrdU assay (Roche Applied Science, Monza, Italy) was used. The assay 
is based on the measurement of BrdU incorporation during DNA synthesis. Cells were seeded 
(1.5X105/well) in 96 wells plates and cultured for 24 hours. JWH133, 10-9, 10-8, 10-7, 10-6 M, 
were added for 24 hours. One control was performed: 
blank: has to be performed in each experimental setup. The blank provides information about 
the unspecific binding of BrdU and anti-BrdU- POD conjugate to the plate. The absorbance 
value obtained in this control has to be subtracted from all other values.  
During this labelling period, the pyrimidine analogue BrdU was incorporated in place of 
thymidine into the DNA of proliferating cells. After removing the culture medium the cells 
were fixed and the DNA was denaturated by adding nuclease for 30 minutes at room 
temperature. This step was essential to improve the accessibility of the incorporated BrdU for 
detection by the antibody. The anti-BrdU-POD was added to cells for 90 minutes at room 
temperature. It bound to the BrdU incorporated in newly synthesized endothelial cellular 
DNA. The immune complexes were detected by the subsequent substrate (TMB) reaction.  
The reaction product was quantified by measuring the absorbance at the respective 
wavelength using Microplate Autoreader at 405nm, reference wavelength 490nm.  
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3.4 Biochemical Evaluation 
3.4.1 Western blot Analysis 
Western Blot analysis have been performed on samples of homogenised lung. Briefly, frozen 
samples of lung were de-frozen and than tissue lysed in 150 μl of ice-cold hypotonic lysis 
buffer and incubated on ice for additional 45 min. The total protein extract was obtained by 
centrifugation at 14,000 rpm for 10 min at 4°C. 
Samples (50 g/mL) were subjected to SDS-polyacrylamide gel electrophoresis, and proteins 
were transferred onto nitrocellulose membrane and incubated with one of the following 
antibodies: rabbit anti-CB1 (1:500 v/v; Cayman Chemical, Michigan, USA), rabbit anti-CB2 
(1:200 v/v; Cayman Chemical, Michigan, USA), rabbit anti-FAAH (1:200 v/v; Cayman 
Chemical, Michigan, USA), rabbit anti-MAGL (1:250 v/v; Cayman Chemical, Michigan, 
USA). Appropriate peroxidase-conjugated secondary antibodies (1:2000 v/v; PerkinElmer 
Massachusset, USA) were used, and proteins were visualized using an enhanced 
chemiluminescence kit (PerkinElmer Massachusset, USA). Protein expression was quantified 
by densitometric analysis of the acquired images by ImageQuant 400 (GE Healthcare) and a 
computer program (Quantity One, Bio-Rad, Hercules, CA). 
 
3.4.2 ELISA assay 
For the quantitative determination of mouse Vascular Endothelial Growth Factor (VEGF) 
concentrations in Quantikine® mouse VEGF Immunoassay (R&D Systems, Minneapolis, 
MN) was used. VEGF levels were determined in tumor extracts, obtained by homogenization, 
by solid phase  ELISA using an immunoassay for mouse samples. This assay employs the 
quantitative sandwich enzyme immunoassay technique. Briefly, samples were stored at lower 
-20°C temperature until use. After adding 50μ l of Assay Diluent RD1N, 50μ l of standards 
(composed of dilution of mouse VEGF standard from 500pg/ml to 7.8 pg/ml; minimum 
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detectable dose ranged from 3.9-25 pg/ml according to manufacture data sheet), control 
(given with kit) and samples were added to the pre-coated plate. 
The plate was covered and incubated two hours at room temperature on a horizontal 
microplate shaker. Five washings were performed with 400μ l Wash Buffer to ensure the 
removal of any unbound substances. 100μ l of Mouse VEGF Conjugate were added to each 
well and the plate was incubated for one hour at room temperature on the shaker. Five 
washings were performed and 100μ l of Substrate Solution were added to each well. After 30 
minutes of incubation at room temperature on the bench top protected from light, 100μ l of 
Stop solution were added to each well, gently tapping the plate to ensure thorough mixing. 
The optical density of each well was determine within 30 minutes, using the Microplate 
Autoreader ELISA (BioRad) set to 450 nm, reference wavelength 570nm. Standard curve and 
quantitative analysis were obtained using the specific Microplate Autoreader Software.  
 
3.4.3 Mouse Angiogenesis Array Kit/Proteome ProfilerTM 
To analyze the expression profiles of tumor-related proteins we used the Proteome ProfilerTM 
Mouse Antibody Array Kit (R&D Systems, Abingdon, UK), according to the Manufacturer‟s 
instructions. This kit uses an array of 53 specific antibodies directed at proteins involved in 
tumor angiogenesis, spotted onto a nitrocellulose membrane. Tissue lysates were centrifuged 
and mixed with 1.5 ml of biotinylated detection antibody for 1 h at room temperature. Then, 
the membranes were incubated with the sample/antibody mixtures overnight at 4°C on a 
rocking platform. Following a washing step to remove unbound material, streptavidin–
horseradish and chemiluminescent detection reagents were added sequentially. Data on 
developed X-ray film were quantified by densitometric analysis with a computer program 
(Quantity One, Bio-Rad, Hercules, CA). An averaged signal from the positive controls of 
each membrane was subtract from each protein spot.  
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3.5 Histological Investigations 
3.5.1 Hematoxylin and Eosin (H&E) staining 
Left lung lobes were fixed in OCT (optimum cutted temperature) medium (Pella, Milan, 
Italy), and 7-m cryosections were cut. H&E staining was performed and used to measure the 
tumor burden. Tumor lesions were analyzed by using serial lung cryosections and expressed 
as tumor lesions/lung (area mm2), as determined by the ratio of the tumor lesions area 
compared with the total lung area (Image J Software, National Institutes of Health, Bethesda, 
MD).  
 
3.5.2 Blood vessels Evaluation  
Lung was, previously, perfused by intra-tracheal injection of formaldehyde 4%. Paraffin 
sections (7 m) from lung lobes were deparaffinised and endogenous peroxidase activity was 
blocked by incubating with 0.3% H2O2 following antigenic recovery. The sections were 
incubated with the primary antibody against CD31 (1:100; Novus Biologicals, Cambrige, 
UK), diluted in PBS. CD31/ PECAM-1 is an angiogenic marker; it plays a role in adhesive 
interactions between adjacent endothelial cells, as well as between leukocytes and endothelial 
cells. The binding of CD31 to the surfaces of leukocytes results in the increase of functional 
leukocyte integrins and in the diapedesis across the endothelium. CD31 is expressed in all 
continuous endothelia, including those of the arteries, arterioles, venules, veins and not 
sinusoidal capillaries, but is not expressed on the discontinuous endothelium, for example in 
the splenic red pulp. In addition, CD31 is expressed diffusely on the surfaces of 
megakaryocytes, platelets, myeloid cells, natural killer cells and certain subsets of T cells, as 
well as B cells precursors (Muller et al., 1997).  
Sections, incubated with isotype matched antibodies, were used as negative controls. 
Subsequently, sections were incubated with biotinylated anti-rabbit secondary antibody 
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(1:200, Dako, Denmark), washed and incubated for 5 min with streptavidin–HRP (1:200; 
Sigma-Aldrich, Milan, Italy). Finally, exposed to diaminobenzidine chromogen with 
haematoxylin counterstain. The slides were then dehydrated and mounted in Entellans 
medium. Images were acquired with Leica DFC320 video camera (Leica, Italy) connected to 
the microscope (Leica, DMRB) using the Leica Application Suite software V2.4.0.  
 
3.6 Statistical Analysis 
Results are expressed as the means ± S.E.M. of n experiments. Statistical significance was 
calculated by one-way analysis of variance (ANOVA) and Turkey-corrected P-value for 
multiple comparison tests. The level of statistically significant difference was defined as 
P<0.05. Linear associations between variables were assessed by the use of standard- least-
square linear regression. Correlation coefficient (r) was presented as measure of linear 
association for regression relationship.  
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4. Results 
 
4.1 Deregulation of ECS during tumor growth  
4.1.1 Evaluation of ECS expression during tumor progression 
In lung tumoral tissue, from 3th to 13th after LLC1 implantation, analysis of Western blot 
exhibited significant increase about the expression of FAAH levels, in tumoral tissues. In 
parallel with the FAAH expression, it was observed, also, a significant increase of levels of 
MAGL expression, in tumoral tissues. 
Our experiments showed, from 13th days, an increase of FAAH and MAGL expression in the 
second tumoral phase, a phase of tumoral consolidation/progression.  
 
 
 
 
 
 
 
 
 
 
Fig. 16: FAAH and MAGL expression in lung cancer: Western blot analysis show that the expression of FAAH and 
MAGL, was significantly increased in lung of mice injected with LLC cells (13 days) mice. Results are expressed as mean 
value ± S.E.M. *P<0.05; **P<0.01 vs 3 days.  
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Moreover, we, also, investigated the expression profile of the main cannabinoids receptor: 
CB1 and CB2. 
Western blot analysis, showed a selected increase in CB2 expression in tumoral tissues, 15
th 
days after tumor induction; while CB1 receptor expression held steady in this advanced phase.  
 
 
                                                     
 
 
 
 
 
 
 
Fig. 17: CB1 and CB2 receptor expression in lung cancer: Western blot analysis show that the expression of CB2, but not 
CB1 receptor, was significantly increased in lung of mice injected with LLC cells (15 days. Results are expressed as mean 
value ± S.E.M. *P<0.05 vs 3 days.  
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4.2 Effect of CB2 agonist on angiogenesis during cancer process 
 
4.2.1 Effect of JWH133 on tumor burden 
Tumor burden was evaluated on tissue small slices (7m) stained with H&E coloration. 
Tumor burden was normalized in relation with tumoral mass area (mm2). 
JWH133 (0.5, 1, 5 g/mouse i.p.) was administered, daily, in mice, from 13th to 17th days 
after cells implant. It was observed that the treatment with JWH133, significantly reduced the 
tumoural area in lung carcinoma mice as compared to PBS treated mice.  
                                                    
 
 
 
 
 
 
 
 
 
Fig.18: Effect of JWH 133 on tumor-burden. Treatment with JWH133 significantly reduced the tumor area in LLC-
implanted mice compared to PBS, 17 days after cell implantation. Results are expressed as mean value ± S.E.M. **P<0.01 vs 
PBS.  
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4.2.2 Effect of JWH133 on VEGF expression in lung   
To evaluate if the reduction of tumoural mass was paralleled with a decrease of angiogenic 
process, we measured VEGF levels, since it has a key role in the process of new blood vessels 
formation. VEGF levels expression was evaluated  by ELISA assay.  
ELISA assay revealed that the administration of JWH 133 (0.5-5 μg/mouse), significantly, 
decreased VEGF expression in lung carcinoma, in confront to PBS treated mice.  
 
 
                                                                                                 
 
 
 
 
 
 
 
 
Fig.19: Effect of JWH 133 on VEGF expression in lung cancer. ELISA assay revealed that the treatment with JWH 133 
(0.5-5 μg/mouse) significantly reduced VEGF level in the lung of tumor-bearing mice compared to PBS, 17 days after cell 
implantation. Results are expressed as mean value ± S.E.M. *P<0.05 vs PBS  
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4.2.3 Effect of JWH133 on 53 angiogenic markers expression in lung 
We decided to performe a  Proteome ProfilerTM array; a multiarray useful to evaluated, 
contemporarily, the expression of 53 proteins involved in angiogenic process. In lung, 
analysis of these proteins revealed a decrease of numerous pro-angiogenic mediators; in 
particular, treatment with JWH133 (1 g/mouse) evidenced  a decrease  of CXCL16, MMP-9, 
MMP-3, IGFBP-2, IGFBP-3 in confront to PBS treated mice (data not show). Moreover, 
another experiment, with JWH133 at the dose of 5 g/mouse, evidenced the reduction of 
expression of a greater number of these mediators (Angiopoietins, CXCL16, MMP-9, MMP-3 
SDF-1, Endoglin, HGF, IGFBP-2, IGFBP-3, Osteopontin) in treated mice compared to un-
treated mice. 
          
(A)
Fig.20: Effect of JWH 133 on angiogenic markers expression.Proteome ProfilerTM array. (A) Representative images of 
two minutes exposed X-Ray film; (B) Densitometric analysis of each angiogenesis related protein. Data are expressed as 
average of pairs of spots.  
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4.2.4 Effect of JWH133 on vessels number in lung carcinoma 
An additional proof about the angiogenic effect of JWH133, was achieved by the count of the 
numbers of vessel in total lung area and in tumoral lung area. Starting to the assumption that, 
after release of VEGF, angiogenic process prosecutes with its binding to the endothelial cell 
receptor, evaluation of the expression of CD31, as a marker of endothelial cells and therefore 
of blood vessels, were performed. 
Immunochemistry analysis evidenced that the treatment with JWH133 (1 g/mouse), does not  
reduce the number of blood vessels number in total lung, compared to un-treated mice. On the 
other hand, it was evaluated tumoral angiogenesis counting the number of vessels  only in 
tumoural mass. In line with previously experiments, JWH133, at the dose of 1g/mouse, 
reduced, significantly, the number of tumoral vessels/mm2 in confront to mice that received 
only PBS.  
Finally, were counted the number of micro-vessels in tumoral mass; our data suggested that 
treatment with JWH133 (1g/mouse) reduced neo-angiogenesis, as revealed by a reduction of 
micro-vessels.  
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Fig.21: Effect of JWH133 on vessels number in lung carcinoma. Immunochemistry analysis evidence that 
treatment with JWH133 significantly reduced number of blood vessel in (A) total lung area and in (B) tumoral lung area.  
Moreover, JWH133, also, reduce the (C) number of micro-vessel in tumoral lung area. Results are expressed as mean value ±  
S.E.M. *P<0.05 vs PBS.  
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4.3 Effect of JWH133 on LLC1 viability and proliferation in vitro 
In order to clarify JWH133 action, distinguishing between a direct action on tumoral cells 
viability or on surrounding cells, in vitro experiments were performed.  
First of all, to evaluate JWH133 effect, on LLC1 viability, MTT assay was conducted. 
Confluent LLC1 cells were treated with JWH133 (10-9, 10-8, 10-7, 10-6 M)  and MTT assay 
was performed after 24 hours of incubation. MTT assay showed any significant variation in 
cells viability in  LLC1 treated compared to un-treated cells.  
In parallel, LLC1 stimulated with JWH133 (10-9, 10-8, 10-7, 10-6 M)  for 24 hours, revealed 
any variation in their proliferation, in confront to un-treated cells as revealed by BrdU assay.  
 
 
 
 
 
 
 
 
 
 
 
Fig.22: Effect of JWH133 on LLC1 viability and proliferation. MTT and BrdU assay showed any significant variation in 
cells viability and proliferatin.  
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4.4 Effect of JWH133 on tumor burden and on VEGF expression in CB2 KO mice 
To confirm the role of CB2 receptors in the modulation of lung cancer, CB2 knockout mice 
have been used.  
The administration of JWH133 in CB2 KO mice, revealed any significant variation on tumor 
burden of treated mice compared to PBS treated mice.  
Tumor burden of treated mice is comparable to tumor burden of un-treated mice. Moreover, 
also the expression of VEGF levels resulted unvaried; in fact in lung of mice treated with 
JWH133 (5 g/mouse) there was no change in expression of VEGF levels in confront to mice 
treated with PBS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.23: Effect of JWH133 on tumor burden and on VEGF expression in CB2 KO mice. JWH133 treatment have no 
effect on these parameters in CB2 KO mice. 
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4.5 Effect of MAGL inhibitor on angiogenesis  
 
4.5.1 Effect of JZL184 on tumor burden 
To validate the pharmacological activity of cannabinoids on the control of tumoral condition, 
we used a different strategy with MAGL enzyme inhibitor, JZL184.. 
In line with the experiments performed with CB2 agonist, mice treated with JZL184 (5, 10, 20 
g/mouse), daily from13th to 17th, showed a, significant and dose-dependent , reduction of 
tumor burden in confront to PBS mice.  
                                     
 
 
 
 
 
 
 
 
 
Fig.25: Effect of JZL184 on tumor-burden. Treatment with JZL184 significantly reduced the tumor area in LLC-implanted 
mice compared to PBS, 17 days after cell implantation. Results are expressed as mean value ± S.E.M. *P<0.05 vs PBS.  
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4.5.2 Effect of JZL184 on VEGF expression in lung   
In order to evaluated if JZL184 action on tumor burden was linked to its activity in 
modulating angiogenic process, ELISA assay for VEGF have been performed.  
Our data reported a significant decrease of VEGF content in lung of mice treated with JZL184 
20g/mouse, compared to mice treated with PBS.  
                                       
 
 
 
 
 
 
 
 
 
Fig.26: Effect of jzl184 on VEGF expression in lung cancer. ELISA assay revealed that the treatment with JZL1884 (0.5-5 
μg/mouse) significantly reduced VEGF level in the lung of tumor-bearing mice compared to PBS, 17 days after cell 
implantation. Results are expressed as mean value ± S.E.M. *P<0.05 vs PBS  
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4.5.3 Effect of JZL184 on 53 angiogenic markers expression in lung 
Last, in order to strengthen anti-angiogenic activity of JZL184, a Proteome ProfilerTM array 
has been executed. This test showed a reduction of several pro-angiogenic factors, in mice 
treated with JZL184 (20g/mouse) compared to untreated mice; these data suggested that the 
decreased tumor mass by JZL184 treatment may be caused by a decrease of expression of 
several angiogenesis-related proteins. 
 
               (A)    
 
 
(B) 
 
Fig.26: Effect of ZL184 on angiogenic markers expression.Proteome ProfilerTM array. (A) Representative images of two 
minutes exposed X-Ray film; (B) Densitometric analysis of each angiogenesis related protein. Data are expressed as average 
of pairs of spots.  
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5. Discussion 
 
In 1976 for the first time, Cannabis derivates have been proposed as a potential 
pharmacological strategy for treating lung carcinoma (White et al., 1976). Since then, several 
studies have reinforced this hypothesis, although a possible in the mechanism of action of 
Cannabis derivates was not completely understood yet. Lung carcinoma represents, 
nowadays, the main cause of cancer-related death (Torre et al., 2015). The mechanisms 
promoting transformation and tumor growth are different but recent guidelines identify, in 
tumor angiogenesis, one of the main responsible. Particularly in lung, a well vascularized 
tissue, the inhibition of angiogenic process represents an useful target to control tumor growth 
(Kim and Murren, 2002).  
Based on these evidences, aim of this thesis, was to investigate the role of endocannabinoid 
system (ECS) and its effect in a model of lung carcinoma in mice, focusing the attention on its 
possible role on angiogenic process.  
 
In order to study the ECS deregulation, we evaluated the expression of the principal enzymes 
involved in endocannabinoids (eCBs) metabolism (FAAH, MAGL) and the expression of the 
main eCB receptors (CB1, CB2). We found a strong deregulation of ECS in the second phase 
of tumor growth; in particular, we found an increase of eCBs degradation enzymes and a 
selective increase of CB2 receptor expression in tumor mass.  
In order to clarify the role of CB2 over-expression, we tried  a pharmacological approach with 
JWH133, a CB2 full agonist.  
Several evidences reported in preclinical studies show that, JWH133 had anti-tumoral effects; 
in fact this molecule caused inhibition of AKT-Regulate COX-2/PGE2 signaling pathway 
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promoting apoptosis in breast cancer (Caffarel et al., 2010); moreover, JWH133 induced G1 
cell cycle arrest on melanoma cells, through the inhibition of p-Akt (Blazquez et al., 2006).  
In our experiments, the treatment with JWH133, during the progression phase of tumor, 
significantly reduced tumor burden. Similarly, we found that the treatment with JWH133 was 
able to decrease the content of VEGF, the key molecule in the process of new blood vessels 
formation. The importance of VEGF in tumor growth is confirmed by the recent approval, in 
cancer therapy, of Bevacizumab (Avastin, Roche), an humanize monoclonal antibody direct 
on VEGF (Presta et al., 1997). The treatment with this antibody, in association with the 
classical chemotherapy based on platinum, showed a significant amelioration of lung 
carcinoma affected patients survival (Sandler et al., 2006).  
In our experiments the effect of JWH133 was not limited to VEGF content reduction, but  it 
involved other pro-angiogenic mediators as revealed by the oligoarray of 53 mouse 
angiogenesis related proteins, many of which (i.e angiopoietin1, chemokines as CXCL16 e 
SDF-1, endothelial markers of proliferation as, endoglin and metallo-proteases, MMP-3, 
MMP-9) resulted decreased. The restore of balance between pro- and anti-angiogenic factors 
by JWH133 treatment was, also, confirmed by the reduction in vessel number in the tumoral 
area and, particularly, by a decrease of micro-vessels number, which are typical of tumoral 
neo-angiogenesis. These promising results, identifying the activation of CB2 to slow down 
tumor progression based on angiogenesis, are perfectly in line with several studies 
demonstrating antiangiogenic effects of CB2 agonists in several types of solid tumors both in 
vitro and in vivo studies.  
Guzman and its colleagues, in 2004, demonstrated that incubation of C6 glioma cells with 
both natural and synthetic cannabinoids, inhibited VEGF release into the medium in a time 
dependent manner (Guzman et al., 2004). They also showed that Cannabinoid- induced 
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attenuation of VEGF production was evident in another glioma cell line (the human 
astrocytoma U373 MG) (Blazquez et al., 2004). 
In accordance to this, we wished to discriminate between a direct action on cancer cells or on 
the cells surrounding the tumor, to distinguish between JWH133 anti-proliferative or anti-
angiogenic effect. First of all, we assessed the effects of JWH133 on Lewis Lung Carcinoma 
cells (LLC1) in vitro. Treatment with JWH133 had no effect on either the viability or 
proliferation of LLC1, suggesting that the reduction of the tumor mass, previously observed 
in vivo, could not be a direct effect on cancer cell, but rather on the micro-environment, i.e. all 
the events that lead to the consolidation and tumor progression, including angiogenesis (Bocci 
et al., 2013). This result opened up the possibility for a treatment with less side effects 
compared to traditional anti-tumoral drugs. 
In order to understand JWH133 effect, CB2 knockout mice have been used too. When 
JWH133 were administrated in CB2 knockout mice underwent to lung cancer development, it 
lost its ability to reduce tumor burden and VEGF content, confirming the importance of CB2 
and this effect. 
Despite the evidence of a therapeutic effect of CBs, their effective introduction into clinical 
use is still controversial and strongly limited by central effects shown by many of them 
(psychotropic effect). An alternative approach may derive from the use of indirect 
cannabinoid agonists, i.e. from those drugs that potentiate eCB tone inhibiting their 
degradation. This strategy may have lower side effects because it would allow the up-
regulation of the eCB tone only in the area where the eCB machinery is activated and 
deregulated, i.e. in lung tumor, as it happens in our experimental model.  
In our study we decided to potentiate the 2-AG pathway since this eCB is the preferential 
ligand on CB2 receptor; for our aim, we used an inhibitor of Monoacylglycerol lipase, the 
JZL184 compound. It has been reported that JZL184 dramatically elevates brain levels of 2-
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AG, in different animal model (Blankman et al., 2007; Long et al., 2009; Nomura et al., 
2011). 
In our experiments, the administration of JZL184, significantly and a in a dose dependent 
manner, reduced lung tumor mass in parallel with a decrease in VEGF levels in the lungs of 
treated animals. Moreover, in the same experimental conditions, we demonstrated that a large 
number of pro-angiogenic mediators, MMP-9, FGF, acid and basic, Endoglin and 
Angiopoietina1, were reduced by treatment with JZL184.  
Our data corroborate the abundant evidences showing  that eCB and cannabinoids, natural and 
synthetic, possess anti-angiogenic effects and thus can counteract the growth and progression 
of many cancers types (Pisanti et al., 2013).  
In conclusion, the deregulation of ECS that, for the first time, we evidenced in a mice model 
of lung cancer, can be the target of therapeutic interventions directed to control the 
angiogenesis, to promote tumor shrinkage. Moreover, the results obtained in this thesis 
identify ECS related molecules, as CB2 selective agonists or inhibitors of degradation of 
eCBs, as possible agents co-adjuvants of conventional anti-cancer therapies. In fact, these 
drugs, in parallel to reducing tumor growth, offer the opportunity to resolve the high costs and 
side effects of the classical anti-angiogenic drugs actually used in therapy.  
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